Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JD Sports-backed Applied Nutrition preparing for £1bn London float - report

(Sharecast News) - Applied Nutrition, a manufacturer of sports supplements part-owned by JD Sports Fashion, is reportedly beginning preparations for a £1bn London flotation. According to Sky News, Liverpool-based Applied Nutrition has been interviewing investment bankers in recent weeks about a listing that could take place in the autumn.

City sources told Sky at the weekend that Deutsche Numis was among those in contention for a role on the float, which could rank among the largest in the UK this year.

One person close to the situation cautioned that no firm decision had been taken to press ahead with an initial public offering.

Founded in 2014, Applied Nutrition formulates and makes premium nutrition supplements for professional athletes and gym enthusiasts.

It is the official nutrition partner of a range of English Football League clubs, including League One's Bolton Wanderers, and the Scottish Premiership side Glasgow Rangers.

JD Sports owns just under a third of the shares, while Applied Nutrition's founder, Thomas Ryder, holds a majority stake. Sky said the remaining shares are understood to be owned by Steven Granite, the company's chief operating officer.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.